BACKGROUND: Endothelial lipase (EL) is a plasma lipase that we previously reported to be significantly correlated with all features of the metabolic syndrome in humans, including directly with measures of adiposity and inversely with high-density lipoprotein cholesterol levels. We hypothesized that inflammation associated with obesity results in upregulation of EL. We determined the relationship between inflammatory markers and EL levels in a cohort of healthy persons recruited on the basis of family history of coronary disease. Furthermore, we directly tested the hypothesis that plasma EL concentrations would increase with induction of an inflammatory state by low-dose endotoxin in humans. METHODS AND RESULTS: High-sensitivity C-reactive protein, interleukin 6, soluble tumor necrosis factor receptor II, soluble intercellular adhesion molecule 1, leptin, and adiponectin were measured in plasma of 858 subjects. Significant direct correlations (P<0.001 for all) were found between EL concentrations and high-sensitivity C-reactive protein (r=0.28), interleukin-6 (r=0.22), soluble tumor necrosis factor receptor II (r=0.22), soluble intercellular adhesion molecule 1 (r=0.24), and leptin (r=0.20). An inverse correlation was present with adiponectin (r=-0.15, P<0.001). Adiponectin inhibited the tumor necrosis factor-alpha-stimulated EL secretion from cultured human coronary endothelial cells in a dose-dependent manner. Experimental low-dose endotoxemia in 20 subjects resulted in a 2.5-fold increase in EL concentrations 12 to 16 hours after injection, which correlated temporally with decreases in both total and high-density lipoprotein phospholipid. CONCLUSIONS: In humans, plasma inflammatory markers are directly correlated with plasma EL concentrations, and experimental endotoxemia significantly increases plasma EL concentrations, proving that EL is upregulated by inflammation in humans. This mechanism may partially explain the low high-density lipoprotein cholesterol levels seen in obesity and metabolic syndrome.
BACKGROUND:Endothelial lipase (EL) is a plasma lipase that we previously reported to be significantly correlated with all features of the metabolic syndrome in humans, including directly with measures of adiposity and inversely with high-density lipoprotein cholesterol levels. We hypothesized that inflammation associated with obesity results in upregulation of EL. We determined the relationship between inflammatory markers and EL levels in a cohort of healthy persons recruited on the basis of family history of coronary disease. Furthermore, we directly tested the hypothesis that plasma EL concentrations would increase with induction of an inflammatory state by low-dose endotoxin in humans. METHODS AND RESULTS: High-sensitivity C-reactive protein, interleukin 6, soluble tumor necrosis factor receptor II, soluble intercellular adhesion molecule 1, leptin, and adiponectin were measured in plasma of 858 subjects. Significant direct correlations (P<0.001 for all) were found between EL concentrations and high-sensitivity C-reactive protein (r=0.28), interleukin-6 (r=0.22), soluble tumornecrosis factor receptor II (r=0.22), soluble intercellular adhesion molecule 1 (r=0.24), and leptin (r=0.20). An inverse correlation was present with adiponectin (r=-0.15, P<0.001). Adiponectin inhibited the tumor necrosis factor-alpha-stimulated EL secretion from cultured human coronary endothelial cells in a dose-dependent manner. Experimental low-dose endotoxemia in 20 subjects resulted in a 2.5-fold increase in EL concentrations 12 to 16 hours after injection, which correlated temporally with decreases in both total and high-density lipoprotein phospholipid. CONCLUSIONS: In humans, plasma inflammatory markers are directly correlated with plasma EL concentrations, and experimental endotoxemia significantly increases plasma EL concentrations, proving that EL is upregulated by inflammation in humans. This mechanism may partially explain the low high-density lipoprotein cholesterol levels seen in obesity and metabolic syndrome.
Authors: Joanne M Wroblewski; Anisa Jahangiri; Ailing Ji; Frederick C de Beer; Deneys R van der Westhuyzen; Nancy R Webb Journal: J Lipid Res Date: 2011-09-27 Impact factor: 5.922
Authors: Harold D Love; S Erin Booton; Braden E Boone; Joan P Breyer; Tatsuki Koyama; Monica P Revelo; Scott B Shappell; Jeffrey R Smith; Simon W Hayward Journal: PLoS One Date: 2009-12-21 Impact factor: 3.240
Authors: Monika Riederer; Pauli J Ojala; Andelko Hrzenjak; Wolfgang F Graier; Roland Malli; Michaela Tritscher; Martin Hermansson; Bernhard Watzer; Horst Schweer; Gernot Desoye; Akos Heinemann; Sasa Frank Journal: J Lipid Res Date: 2010-07-07 Impact factor: 5.922
Authors: Jon J Hangeland; Lynn M Abell; Leonard P Adam; Ji Jiang; Todd J Friends; Lauren E Haque; James Neels; Joelle M Onorato; Alice Ye A Chen; David S Taylor; Xiaohong Yin; Thomas W Harrity; Michael D Basso; Richard Yang; Paul G Sleph; David A Gordon; Christine S Huang; Ruth R Wexler; Heather J Finlay; R Michael Lawrence Journal: ACS Med Chem Lett Date: 2018-06-15 Impact factor: 4.345
Authors: Caren E Smith; Donna K Arnett; Michael Y Tsai; Chao-Qiang Lai; Laurence D Parnell; Jian Shen; Martin Laclaustra; Mireia Junyent; José M Ordovás Journal: Atherosclerosis Date: 2009-03-25 Impact factor: 5.162